Free Daily Podcast Summary
CME in Minutes: Education in Oncology & Hematology: Daily Summaries Delivered
by Answers in CME
Get answers in 25 minutes or less from world-class experts and earn CME/CE credit with CME in Minutes: Education in Oncology & Hematology by Answers in CME. Benefit from digests of latest advancements, thoughtful case studies, and nuanced perspectives. Inspiring and engaging programs designed for oncologists and hematologists to cover the diagnosis, staging, treatment, follow-up, and clinical management of tumors and hematological malignancies. Earning your CME/CE credits has never been faster or easier. Visit the URL for each individual program to request continuing education credit or access the slides.
Latest Episodes
The most recent episodes — sign up to get AI-powered summaries of each one.
- 2 days ago1h 4m
Clinical Pearls for Subcutaneous Delivery: Optimizing Anti-CD38 Use in Multiple Myeloma
Please visit answersincme.com/860/2026-MC-001665-replay to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Ajai Chari, MD; Caitlin Costello, MD; and Beth Faiman, PhD, MSN, APN-BC, TCTCN, AOCN, FAAN, FAPO. In this activity, experts in multiple myeloma (MM) discuss the therapeutic rationale, clinical data, and practical integration of subcutaneous anti-CD38 therapies to optimize care for patients with MM. Upon completion of this activity, participants should be better able to: Recognize the rationale for using subcutaneous (SC) formulations of anti-CD38 monoclonal antibodies in patients with multiple myeloma (MM); Assess the clinical profiles of approved and emerging SC formulations of anti-CD38 monoclonal antibodies in patients with MM; and Outline evidence-based, patient-centered strategies for optimizing outcomes with SC formulations of anti-CD38 monoclonal antibodies in patients with MM.
- 2 weeks ago1h 1m
Expanding the Use of HER2-Directed ADCs Into Early-Stage Breast Cancer: Multidisciplinary Conversations on (Neo)Adjuvant Care
Please visit answersincme.com/860/101385133-replay to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Peter A. Fasching, MD; Michael Gnant, MD, FACS; and Cristina Saura Manich, MD, PhD. In this activity, experts in breast cancer discuss new evidence in neoadjuvant and adjuvant care of early disease. Upon completion of this activity, participants should be better able to: Describe multidisciplinary viewpoints on the role that HER2-directed ADCs may play in the (neo)adjuvant setting for HER2-positive early-stage breast cancer; Evaluate evidence for the (neo)adjuvant use of HER2-directed ADCs in the multidisciplinary management of HER2-positive early-stage breast cancer; and Formulate evidence-based multidisciplinary strategies to optimally incorporate (neo)adjuvant HER2-directed ADCs into the treatment paradigm for HER2-positive early-stage breast cancer.
- 2 weeks ago23 min
Personalized Treatment Strategies With First-Line Immunotherapy-Based Regimens in Advanced Colorectal Cancer and Biliary Tract Cancer
Please visit answersincme.com/PNQ860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Rachel Goodwin, MSc, MD, FRCPC; and Vincent Tam, MD. In this activity, experts in colorectal cancer and biliary tract cancer discuss first-line immunotherapy considerations. Upon completion of this activity, participants should be better able to: Evaluate the clinical profiles of first-line immunotherapy-based regimens for the treatment of patients with advanced colorectal cancer (CRC); Formulate strategies to individualize first-line immunotherapy-based regimens for patients with advanced CRC; Describe the clinical evidence on first-line immunotherapy-based regimens for patients with advanced biliary tract cancer (BTC); and Apply patient-, drug-, and disease-specific considerations to optimize first-line immunotherapy-based regimens for patients with advanced BTC.
- 3 weeks ago14 min
KIT D816V in Focus: Optimizing Diagnosis and TKI Therapy in Advanced Systemic Mastocytosis
Please visit answersincme.com/CKX860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Prithviraj Bose, MD. In this activity, an expert in hematology discusses the role of current and emerging treatment options for patients living with advanced systemic mastocytosis. Upon completion of this activity, participants should be better able to: Identify prognostic features of advanced systemic mastocytosis (AdvSM) that guide diagnosis and care planning; Describe current and emerging treatment options for patients with AdvSM; and Evaluate patient- and disease-related strategies that inform treatment selection in AdvSM.
- 3 weeks ago14 min
Cracking the Code of KRAS-Mutant NSCLC: Evidence for Emerging Therapies in First-Line Settings
Please visit answersincme.com/GYB860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Pasi A. Jänne, MD, PhD, FASCO. In this activity, an expert in oncology discusses the role of emerging KRAS inhibitors in the treatment paradigm for non–small-cell lung cancer (NSCLC). Upon completion of this activity, participants should be better able to: Explain the rationale for targeted therapy in previously untreated patients with KRAS-mutant NSCLC in the context of current standard of care with chemoimmunotherapy; Interpret the clinical evidence for emerging KRAS inhibitors in patients with previously untreated NSCLC; and Propose how emerging KRAS inhibitors may fit into the treatment paradigm for treatment-naive patients with KRAS-mutant NSCLC.
- 3 weeks ago16 min
Sebastien J. Hotte, MD, FRCPC - An Integrated Approach to Optimizing Radioligand Therapy and Bone Health Management in mCRPC
Please visit answersincme.com/NZU860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Sebastien J. Hotte, MD, FRCPC. In this activity, an expert in oncology discusses radioligand therapy for metastatic castration-resistant prostate cancer. Upon completion of this activity, participants should be better able to: Evaluate how the current guidelines and evidence may inform the sequencing of radioligand therapies in patients with metastatic castration-resistant prostate cancer (mCRPC); Apply evidence-based approaches to optimally sequence radioligand therapies in patients with mCRPC; and Identify strategies to optimize bone health management in patients with mCRPC.
- 4 weeks ago36 min
30-Minute Power Briefing: ICIs in Frontline Advanced Classical Hodgkin Lymphoma—What’s New and What’s Now?
Please visit answersincme.com/860/102771731-replay to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Sairah Ahmed, MD; and Sharon Marie Castellino, MD, MSc. In this activity, experts in Hodgkin lymphoma discuss unmet needs and emerging data in the treatment of classical HL. Upon completion of this activity, participants should be better able to: Explain the rationale for investigating ICI-based regimens for previously untreated advanced cHL; Interpret the emerging clinical evidence for ICI-based regimens in patients with previously untreated advanced cHL; and Propose how emerging ICI-based regimens, as they become available, may fit into the treatment paradigm for adult and pediatric patients with previously untreated advanced cHL.
- May 5, 202614 min
From Burden to Breakthrough: The Rise of KIT D816V-Selective Therapy in Indolent Systemic Mastocytosis
Please visit answersincme.com/ZTY860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Daniel J. DeAngelo, MD, PhD. In this activity, an expert in hematology discusses targeted treatment options for the management of indolent systemic mastocytosis. Upon completion of this activity, participants should be better able to: Recognize the impacts of indolent systemic mastocytosis (ISM) on patients’ quality of life; Discuss the clinical significance of selective KIT D816V–targeting tyrosine kinase inhibitors (TKIs) in the management of patients with ISM; and Design patient-centered strategies for integrating selective KIT D816V–targeting TKIs into the management of ISM.
About CME in Minutes: Education in Oncology & Hematology
Get answers in 25 minutes or less from world-class experts and earn CME/CE credit with CME in Minutes: Education in Oncology & Hematology by Answers in CME. Benefit from digests of latest advancements, thoughtful case studies, and nuanced perspectives. Inspiring and engaging programs designed for oncologists and hematologists to cover the diagnosis, staging, treatment, follow-up, and clinical management of tumors and hematological malignancies. Earning your CME/CE credits has never been faster or easier. Visit the URL for each individual program to request continuing education credit or access the slides.
Customized Recaps
AI-powered recaps with compact key takeaways, quotes, and insights.
Straight to Your Inbox
Get key takeaways from CME in Minutes: Education in Oncology & Hematology in a 5-minute read.
Save Hours Every Week
Stay current on your favorite podcasts without falling behind.
Frequently Asked Questions
What is Podzilla's CME in Minutes: Education in Oncology & Hematology daily summary?
It's a free AI-powered email that summarizes new episodes of CME in Minutes: Education in Oncology & Hematology as soon as they're published. You get the key takeaways, notable quotes, and links & mentions — all in a quick read.
How does the CME in Minutes: Education in Oncology & Hematology podcast summary work?
When a new episode drops, our AI transcribes and analyzes it, then generates a personalized summary tailored to your interests and profession. It's delivered to your inbox every morning.
Is this an official CME in Minutes: Education in Oncology & Hematology product?
No. Podzilla is an independent service that summarizes publicly available podcast content. We're not affiliated with or endorsed by Answers in CME.
Can I get summaries of other podcasts too?
Absolutely! The free plan covers up to 3 podcasts. Upgrade to Pro for 15, or Premium for 50. Browse our full catalog at /podcasts.
How often does CME in Minutes: Education in Oncology & Hematology release new episodes?
CME in Minutes: Education in Oncology & Hematology publishes every few days. Our AI generates a summary within hours of each new episode.
What topics does CME in Minutes: Education in Oncology & Hematology cover?
CME in Minutes: Education in Oncology & Hematology covers topics including Science, Medicine, Fitness, Health & Fitness, Life Sciences. Our AI identifies the specific themes in each episode and highlights what matters most to you.
Start getting CME in Minutes: Education in Oncology & Hematology summaries tomorrow morning.
Free forever for up to 3 podcasts. No credit card required.
Free forever for up to 3 podcasts. No credit card required.